Mounting a strategic offense: Fighting tumor vasculature with oncolytic viruses

Fernando A. Angarita, Sergio A. Acuna, Kathryn Ottolino-Perry, Siham Zerhouni, J. Andrea McCart

Research output: Contribution to journalReview articlepeer-review


Blood supply within a tumor drives progression and ultimately allows for metastasis. Many anticancer therapies target tumor vasculature, but their individual effectiveness is limited because they induce indirect cell death. Agents that disrupt nascent and/or established tumor vasculature while simultaneously killing cancer cells would certainly have a greater impact. Oncolytic virotherapy utilizes attenuated viruses that replicate specifically within a tumor. They induce cytotoxicity through a combination of direct cell lysis, antitumor immune stimulation, and recently identified antitumor vascular effects. This review summarizes the novel preclinical and clinical evidence regarding the antitumor vascular effects of oncolytic viruses, which include infection and lysis of tumor endothelial cells, natural or genetically engineered antiangiogenic properties, and combination therapy with clinically approved antivascular agents.

Original languageEnglish (US)
Pages (from-to)378-392
Number of pages15
JournalTrends in Molecular Medicine
Issue number6
StatePublished - Jun 2013


  • Angiogenesis inhibitors
  • Antivascular therapy
  • Oncolytic virotherapy
  • Oncolytic virus
  • Tumor vasculature
  • Vascular disruption

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Mounting a strategic offense: Fighting tumor vasculature with oncolytic viruses'. Together they form a unique fingerprint.

Cite this